Some People with Celiac Disease at an Increased Risk of Lymphoma

Patients with celiac disease whose intestines are slow to heal appear to be at an increased risk of lymphoma.

According to Dr. Peter Green and colleagues from the Celiac Disease Center at Columbia University in New York, people with celiac disease who had persistent damage to their intestines following diagnosis have four times higher risk of developing lymphoma than the general public.

Celiac disease and intestine damage

The study involved more than 7,600 people in Sweden diagnosed with celiac disease and who also had their intestines biopsied a year or so after diagnosis. Researchers found that 43 percent still had damage to their intestines on follow-up.

Those whose intestines had healed following their diagnosis did not appear to be at any higher risk than the general public for lymphoma.

The Swedish patients were followed for an average of nine years after their follow-up biopsy. A total of 53 patients were diagnosed with lymphoma.

The cause?

Speculation is that there might be a lack of adherence to a gluten-free diet, although this is impossible to know for sure.

Approximately 1 percent of Americans suffer from celiac disease, in which the immune system reacts to gluten – a protein found in wheat, barley and rye. Patients are counseled to maintain a gluten-free diet because gluten damages the small intestine, thereby keeping the immune system on overdrive.

The investigators' findings were published in the Annals of Internal Medicine.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap